PT  - JOURNAL ARTICLE
AU  - Xiaolan Wang
AU  - Fan Yao
AU  - Nan Liu
AU  - Yunfei Wu
AU  - Xinyu Zheng
AU  - Jiguang Li
AU  - Caigang Liu
AU  - Xueshan Qiu
AU  - Feng Jin
TI  - Clinical Implications of HER-2 and P53 in Taxane-Based and Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer
AID  - 10.1007/s11805-008-0424-5
DP  - 2008 Dec 01
TA  - Chinese Journal of Clinical Oncology
PG  - 424--428
VI  - 5
IP  - 6
4099  - http://www.cancerbiomed.org/content/5/6/424.short
4100  - http://www.cancerbiomed.org/content/5/6/424.full
SO  - Cancer Biol Med2008 Dec 01; 5
AB  - OBJECTIVE To evaluate the predictive value of human epidermal growth factor receptor-2 (HER-2) and P53 in taxane-based and anthracycline-based neoadjuvant chemotherapy (NAC) in breast cancer.METHODS Sixty-two patients with breast cancer were included in this study. Twenty-two patients were treated with taxane-based (taxane group) and 40 with anthracycline-based (anthracycline group). ER, PR, c-erbB2 and P53 were detected by immunohistochemistry staining before NAC, and Fluorescence In Situ Hybridization(FISH) was used to detect the HER-2 gene amplification for the cases with the expression of c-erbB2 protein as (++) or (+++). The efficacy of the regimens was evaluated after NAC.RESULTS In the anthracycline group, objective response (OR) was observed in 30 out of 40 patients (75%), whereas no response (NR) was observed in 10 patients (25%). In the taxane group, OR was observed in 15 patients out of 22 patients (68.2%), whereas NR was observed in 7 patients (31.8%). HER-2-negative status was correlated with a high OR in both taxane-based and anthracycline-based NAC (P = 0.023 and P = 0.029), whereas P53-negative status was correlated with high OR rate in anthracycline-based NAC (P = 0.041). The significant difference of the CR rates was observed between the patients took < 4 cycles and ≥ 4 cycles NAC (4.65% vs. 21.05%, P < 0.05).CONCLUSION The patients with HER-2 gene non-amplication may be sensitive to both taxane-based and anthracycline-based chemotherapy; the patients without P53 overexpression may suitable to select anthracycline-based chemotherapy; and proper increased NAC cycles may increase CR rates.